BioCardia
Develops cell therapies and catheter systems for heart and lung diseases.
Something off on this page? Send us feedback.
Profile
Develops cell therapies and catheter-based delivery tools for cardiovascular and pulmonary diseases, with CardiAMP pairing patient cell selection and point-of-care processing with cardiac delivery. Revenue is presently tied to collaboration services; product sales await regulatory approval.
Develops autologous and allogeneic cell therapies for ischemic heart failure, refractory angina and acute respiratory distress syndrome. Its CardiAMP system selects and processes a patient’s bone-marrow cells at the point of care, then delivers them into the myocardium through the Helix catheter.
Also develops the Helix delivery platform, cleared Morph and AVANCE vascular-access catheters, and Heart3D imaging software. Collaboration agreements can generate fees for delivery systems, clinical-study training and support, milestones, and potential future therapeutic-revenue participation; current cell-therapy candidates are pre-commercial.
Manufacturing and operations are centered in Sunnyvale, while regulatory work focuses on the United States and Japan. Progress depends largely on CardiAMP clinical development, regulatory authorization, trial enrollment, funding and licensed cell-processing technology manufactured by Biomet Biologics.
Company facts
Key statistics
Year to date −7.1% · Average volume (30d) 243.2K
Analysts
No analyst consensus on record.
Earnings
EPS
Revenue
History
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Next session |
|---|---|---|---|---|---|---|---|
| Aug 12, 2026Q2 FY26 | −$0.18 | −$0.13 | +27.8% | — | — | — | +5.56% |
| May 15, 2026Q1 FY26 | −$0.17 | −$0.21 | −23.5% | — | — | — | −10.88% |
| Mar 24, 2026Q4 FY25 | −$0.20 | −$0.06 | +70.0% | $25.0K | — | — | −0.83% |
| Nov 12, 2025Q3 FY25 | −$0.25 | −$0.24 | +4.0% | — | — | — | −3.08% |
Financial highlights
| 12 quarters | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | |
|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | |
| Gross profit | −$1.5M | −$1.4M | −$107.0K | −$185.0K | −$124.0K | −$124.0K | |
| Operating income | −$2.7M | −$2.1M | −$1.5M | −$2.0M | −$2.3M | −$1.6M | |
| Net income | −$2.7M | −$2.0M | −$1.5M | −$2.0M | −$2.3M | −$1.6M | |
| Diluted EPS | −$0.99 | −$0.40 | −$0.24 | −$0.18 | −$0.21 | −$0.13 | |
| Gross margin | — | — | — | — | — | — | |
| Operating margin | — | — | — | — | — | — |
Fiscal years (4-quarter sums)FY21 $1.0M · FY22 $1.4M · FY23 $477.0K · FY24 $58.0K · FY25 $0
Balance sheet, Jun 30, 2026Cash & short-term investments $4.1M · Total debt $293.0K · Total assets $4.8M · Shareholders' equity $2.7M
Dividends
No dividends on record.
Ownership
Shares outstanding 14.88M · Float 10.19M · 68.5% free float
A Form 4 total here can count shares the filer formally disclaims — an award voted by proxy, for instance — which the holder's own Schedule 13D/G excludes, so where the two disagree the schedule's smaller figure is used.
Top shareholders13F · 13D/G · Form 4
| Holder | Shares | % outstanding | Form | Filed |
|---|---|---|---|---|
| Lincoln Alternative Strategies LLC | 800.0K | 7.54% | 13G | Sep 19, 2025 |
| Simon H. Stertzer · director | 757.4K | 5.09% | Form 4 | Jun 24, 2026 |
| Thomas A. Satterfield, Jr. | 592.1K | 9.90% | 13G | Aug 13, 2025 |
| Peter Altman · director, officer: President and CEO | 381.1K | 2.56% | Form 4 | Aug 18, 2026 |
| Andrew Scott Blank · director | 278.3K | 1.87% | Form 4 | Sep 23, 2025 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Aug 17, 2026 | Peter Altman | director, officer: President and CEO | +5,400 | $0.9300 |
| Aug 13, 2026 | Peter Altman | director, officer: President and CEO | +1,900 | $0.9200 |
| Jul 29, 2026 | Peter Altman | director, officer: President and CEO | +5,000 | $0.7800 |
| Jul 17, 2026 | Peter Altman | director, officer: President and CEO | +500 | $0.8300 |
| Jul 14, 2026 | Peter Altman | director, officer: President and CEO | +2,800 | $0.8800 |
Peers
- Mesoblast (ADR)
Direct ischemic HFrEF cell-therapy rival in the U.S.
CompareAfter-hours close
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| BioCardia | $1.18 | +0.36% | $17.1M | — | — | — | — |
| Mesoblast (ADR) | $17.44 | −0.17% | $2.26B | — | — | 35.0 | +882.8% |
| Median | — | — | 35.0 | +882.8% |